News

Group estimates global cancer cases, deaths in 2015


 

Cancer patient

receiving chemotherapy

Photo by Rhoda Baer

Researchers have estimated the global incidence of 32 cancer types and deaths related to these malignancies in 2015.

The group’s data, published in JAMA Oncology, suggest there were 17.5 million cancer cases and 8.7 million cancer deaths last year.

There were 78,000 cases of Hodgkin lymphoma and 24,000 deaths from the disease, as well as 666,000 cases of non-Hodgkin lymphoma (NHL) and 231,000 NHL deaths.

There were 154,000 cases of multiple myeloma and 101,000 deaths from the disease.

And there were 606,000 cases of leukemia, with 353,000 leukemia deaths. This included 161,000 cases of acute lymphoid leukemia (110,000 deaths), 191,000 cases of chronic lymphoid leukemia (61,000 deaths), 190,000 cases of acute myeloid leukemia (147,000 deaths), and 64,000 cases of chronic myeloid leukemia (35,000 deaths).

The data also show that, between 2005 and 2015, cancer cases increased by 33%, mostly due to population aging and growth, plus changes in age-specific cancer rates.

Globally, the odds of developing cancer during a lifetime were 1 in 3 for men and 1 in 4 for women in 2015.

Prostate cancer was the most common cancer in men (1.6 million cases), although tracheal, bronchus, and lung cancer was the leading cause of cancer deaths for men.

Breast cancer was the most common cancer for women (2.4 million cases) and the leading cause of cancer deaths in women.

The most common childhood cancers were leukemia, “other neoplasms,” NHL, and brain and nervous system cancers.

Recommended Reading

Anti-CD22 CAR T-cells shift ALL into complete remission
MDedge Hematology and Oncology
Halving the TKI dose safe, cost effective in CML patients with stable remissions
MDedge Hematology and Oncology
VIDEO: 33A + ‘7 + 3’ equals good remission numbers in untreated AML
MDedge Hematology and Oncology
VIDEO: Half-dose TKI safe, cost-effective in CML in stable remission
MDedge Hematology and Oncology
VIDEO: CPX-351 may allow more high-risk AML patients to have allogeneic transplants
MDedge Hematology and Oncology
VIDEO: Combination venetoclax-LDAC therapy boosts overall survival in AML
MDedge Hematology and Oncology
VIDEO: Addition of antibody drug conjugate produces deep AML remissions
MDedge Hematology and Oncology
VIDEO: Novel, multi-arm trial aims to beat AML
MDedge Hematology and Oncology
Half of CML patients can stop TKI therapy, study suggests
MDedge Hematology and Oncology
Combo shows early promise in newly diagnosed AML
MDedge Hematology and Oncology